Gothenburg-based company Cortendo has appointed Matthew Pauls as President and Chief Executive Officer.
Prior to joining Cortendo, Mr. Pauls was Chief Commercial Officer of Insmed, Inc, a publicly traded biopharmaceutical company. Mr. Pauls has also worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations. Mr. Pauls also held positions at Bristol-Myers Squibb in Brand Management and Payor Marketing and at Johnson &
Johnson in various US and global commercial roles. He holds BS and MBA degrees from Central Michigan University and a JD from Michigan State University College of Law.
“It is a pleasure to take over the leadership of Cortendo at such a pivotal time in the development of the company. I’m excited about the opportunity to build a premier global biopharmaceutical company dedicated to serving patients who suffer from serious endocrine diseases with emphasis in orphan indications,” said Mr. Pauls.
Matthew Pauls will start his new position at Cortendo starting from August 25, 2014.
Cortendo AB is a biopharmaceutical company headquartered in Göteborg, Sweden, active in the field of cortisol inhibition. The lead drug candidate NormoCort, the 2S, 4R-enantiomer of ketoconazole, has been re-focused to Cushing’s Syndrome, and has entered Phase 3 development.
